Literature DB >> 26499777

The STORM trial and beyond: narrowing the horizon of adjuvant sorafenib for postoperative hepatocellular carcinoma.

Jian-Hong Zhong.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26499777     DOI： 10.1007/s13277-015-4279-0

Source DB:  PubMed          Journal:  Tumour Biol        ISSN： 1010-4283


× No keyword cloud information.
  17 in total

1.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.

Authors: 
Journal:  Eur J Cancer       Date:  2012-03       Impact factor: 9.162

2.  Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.

Authors:  Jordi Bruix; Jean-Luc Raoul; Morris Sherman; Vincenzo Mazzaferro; Luigi Bolondi; Antonio Craxi; Peter R Galle; Armando Santoro; Michel Beaugrand; Angelo Sangiovanni; Camillo Porta; Guido Gerken; Jorge A Marrero; Andrea Nadel; Michael Shan; Marius Moscovici; Dimitris Voliotis; Josep M Llovet
Journal:  J Hepatol       Date:  2012-06-19       Impact factor: 25.083

3.  Sorafenib in advanced hepatocellular carcinoma - We have won a battle not the war.

Authors:  Peter R Galle
Journal:  J Hepatol       Date:  2008-09-09       Impact factor: 25.083

4.  Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: a single-center experience.

Authors:  Wei Zhang; Gang Zhao; Kai Wei; Qingxiang Zhang; Weiwei Ma; Tianqiang Song; Qiang Wu; Ti Zhang; Dalu Kong; Qiang Li
Journal:  Biosci Trends       Date:  2014-12       Impact factor: 2.400

5.  Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: A pilot study.

Authors:  Shen-Nien Wang; Shih-Cheng Chuang; King-Teh Lee
Journal:  Hepatol Res       Date:  2013-06-13       Impact factor: 4.288

6.  Report of incidence and mortality in China cancer registries, 2009.

Authors:  Wanqing Chen; Rongshou Zheng; Siwei Zhang; Ping Zhao; Guanglin Li; Lingyou Wu; Jie He
Journal:  Chin J Cancer Res       Date:  2013-02       Impact factor: 5.087

7.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

8.  Nucleos(t)ide analogue therapy for HBV-related HCC after hepatic resection: clinical benefits and unanswered questions.

Authors:  Jian-Hong Zhong
Journal:  Tumour Biol       Date:  2014-11-28

9.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

10.  Historical Comparison of Overall Survival after Hepatic Resection for Patients With Large and/or Multinodular Hepatocellular Carcinoma.

Authors:  Jian-Hong Zhong; Xue-Mei You; Shi-Dong Lu; Yan-Yan Wang; Bang-De Xiang; Liang Ma; Fei-Xiang Wu; Wei-Ping Yuan; Ying Chen; Le-Qun Li
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817
View more
  8 in total

1.  Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular carcinoma.

Authors:  X Xiang; J-H Zhong; Y-Y Wang; X-M You; L Ma; B-D Xiang; L-Q Li
Journal:  Clin Transl Oncol       Date:  2017-02-03       Impact factor: 3.405

2.  Adjuvant sorafenib in hepatocellular carcinoma: A cautionary comment of STORM trial.

Authors:  Jian-Hong Zhong; Xue-Ke Du; Bang-De Xiang; Le-Qun Li
Journal:  World J Hepatol       Date:  2016-08-18

3.  Sorafenib improves lipiodol deposition in transarterial chemoembolization of Chinese patients with hepatocellular carcinoma: a long-term, retrospective study.

Authors:  Lin Zheng; Chen-Yang Guo; Cheng-Shi Chen; Jin-Cheng Xiao; Hong-Tao Hu; Hong-Tao Cheng; Deng-Wei Zong; Li Jiang; Hai-Liang Li
Journal:  Oncotarget       Date:  2017-06-29

Review 4.  New Evidence and Perspectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.

Authors:  Jun Yin; Wen-Tao Bo; Jian Sun; Xiao Xiang; Jin-Yi Lang; Jian-Hong Zhong; Le-Qun Li
Journal:  J Clin Transl Hepatol       Date:  2017-03-30

5.  Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China: A real-world study.

Authors:  Jian-Hong Zhong; Ning-Fu Peng; Xue-Mei You; Liang Ma; Xiao Xiang; Yan-Yan Wang; Wen-Feng Gong; Fei-Xiang Wu; Bang-De Xiang; Le-Qun Li
Journal:  Oncotarget       Date:  2017-03-14

Review 6.  Harms and benefits of adoptive immunotherapy for postoperative hepatocellular carcinoma: an updated review.

Authors:  Bao-Hong Yuan; Ru-Hong Li; Wei-Ping Yuan; Tian Yang; Tie-Jun Tong; Ning-Fu Peng; Le-Qun Li; Jian-Hong Zhong
Journal:  Oncotarget       Date:  2017-03-14

7.  Strengthening the case that elevated levels of programmed death ligand 1 predict poor prognosis in hepatocellular carcinoma patients.

Authors:  Jian-Hong Zhong; Cheng-Piao Luo; Chun-Yan Zhang; Le-Qun Li
Journal:  J Hepatocell Carcinoma       Date:  2016-12-30

Review 8.  Treatment of hepatocellular carcinoma with portal vein tumor thrombus: advances and challenges.

Authors:  Jin-Fang Jiang; Yong-Cong Lao; Bao-Hong Yuan; Jun Yin; Xin Liu; Long Chen; Jian-Hong Zhong
Journal:  Oncotarget       Date:  2017-05-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.